Somatostatin receptor expression in hepatocellular carcinoma: prognostic and therapeutic considerations.

  title={Somatostatin receptor expression in hepatocellular carcinoma: prognostic and therapeutic considerations.},
  author={Omar Abdel-Rahman and Angela Lamarca and Juan W Valle and Richard A. Hubner},
  journal={Endocrine-related cancer},
  volume={21 6},
Sorafenib is the only systemic therapy to demonstrate a significant survival benefit over supportive care in robust randomised controlled trials for advanced hepatocellular carcinoma (HCC). In the context of an intense search for prognostic and predictive factors for response and efficacy of different systemic therapies (including sorafenib), a number of molecular targets have been identified, paving new avenues for potential therapeutic opportunities. Such molecular targets include… CONTINUE READING

From This Paper

Topics from this paper.


Publications citing this paper.


Publications referenced by this paper.
Showing 1-10 of 57 references

Progression - free survival ( PFS ) with lanreotide autogel / depot ( LAN ) in enteropancreatic NETs patients : the CLARINET extension study . ASCO 2014 Annual Meeting

  • M Caplin
  • Journal of Clinical Oncology
  • 2014
1 Excerpt

Progression-free survival (PFS) with lanreotide autogel/ depot (LAN) in enteropancreatic NETs patients: the CLARINET extension study

  • M Caplin
  • ASCO 2014 Annual Meeting. Journal of Clinical…
  • 2014
1 Excerpt

Similar Papers

Loading similar papers…